CBT as an Adjunct to SRIs in the Treatment of BDD

Status Active, not recruiting

Clinical Trial Summary

The research project is a controlled pilot study of the efficacy of cognitive-behavioral therapy (CBT) as an adjunct to serotonin reuptake inhibitor (SRI) pharmacotherapy in body dysmorphic disorder (BDD). This study assesses the efficacy of CBT in comparison to relaxation and stress management training (RSMT), an active control treatment

Clinical Trial Description

In total, 20 BDD patients aged 16 through 65 will participate. To be eligible they must meet DSM-IV criteria for BDD, have a score of 20 or greater on the BDD modification of the Yale Brown Obsessive-Compulsive Scale (BDD-YBOCS) and be on a stable, therapeutic does of an SRI (at least 12 weeks on the SRI with 8 weeks at a therapeutic dose: acceptable medications (therapeutic daily doses) are citalopram (40mg), clomipramine (150mg), fluoxetine (40mg), fluvoxamine (150mg), paroxetine (40mg), sertraline (50mg), and venlafaxine (150mg). ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00211809
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Active, not recruiting
Phase	Phase 4

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02635152` - Interpretation Bias Modification for Body Dysmorphic Disorder	N/A
Completed	`NCT03673046` - Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)	N/A
Recruiting	`NCT05402475` - Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder	N/A
Withdrawn	`NCT02843451` - Milk Thistle in Body Dysmorphic Disorder	Phase 2
Completed	`NCT02010619` - Internet Delivered CBT for Body Dysmorphic Disorder	N/A
Completed	`NCT00842309` - D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder	Early Phase 1
Completed	`NCT00245635` - Fluoxetine in Pediatric Body Dysmorphic Disorder	Phase 4
Completed	`NCT02808702` - Brain Correlates of Self-Focused Processing	N/A
Completed	`NCT01002326` - Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder	N/A
Active, not recruiting	`NCT01075672` - Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals	N/A
Completed	`NCT02671266` - Oxytocin Administration in BDD and OCD	Phase 2
Completed	`NCT01038128` - An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder	N/A
Completed	`NCT01398865` - Escitalopram Neuroimaging Supplement	N/A
Completed	`NCT00265109` - Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder	Phase 4
Recruiting	`NCT04373629` - Perceptual Abnormalities and Their Malleability in BDD	N/A
Completed	`NCT01453439` - Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder	N/A
Completed	`NCT00871143` - Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)	N/A
Completed	`NCT00106223` - Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder	N/A